Globus Medical, Inc.
Globus Medical, Inc. (GMED) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Globus Medical, Inc. (GMED), covering cash flow, earnings, and balance sheets.
Globus Medical, Inc. (GMED) Income Statement & Financial Overview
Review Globus Medical, Inc. GMED income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $598.12M | $657.29M | $625.71M | $629.69M |
| Cost of Revenue | $195.40M | $263.44M | $300.59M | $289.75M |
| Gross Profit | $402.72M | $363.94M | $325.11M | $339.94M |
| Gross Profit Ratio | $0.67 | $0.55 | $0.52 | $0.54 |
| R&D Expenses | $33.06M | $33.41M | $35.38M | $37.70M |
| SG&A Expenses | $242.80M | $253.48M | $240.74M | $238.12M |
| Operating Expenses | $305.72M | $333.58M | $276.12M | $275.82M |
| Total Costs & Expenses | $501.12M | $597.02M | $576.71M | $565.57M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $775000.00 | $2.33M |
| Depreciation & Amortization | $66.07M | $68.23M | $66.95M | $63.59M |
| EBITDA | $164.13M | $92.89M | $115.94M | $113.50M |
| EBITDA Ratio | $0.27 | $0.14 | $0.19 | $0.18 |
| Operating Income | $97.004M | $60.27M | $48.10M | $64.13M |
| Operating Income Ratio | $0.16 | $0.09 | $0.08 | $0.10 |
| Other Income/Expenses (Net) | $6.66M | -$35.61M | $8.93M | -$2.04M |
| Income Before Tax | $103.67M | $24.67M | $57.03M | $47.58M |
| Income Before Tax Ratio | $0.17 | $0.04 | $0.09 | $0.08 |
| Income Tax Expense | $28.21M | -$1.84M | $5.20M | $15.82M |
| Net Income | $75.46M | $26.50M | $51.84M | $31.76M |
| Net Income Ratio | $0.13 | $0.04 | $0.08 | $0.05 |
| EPS | $0.55 | $0.19 | $0.38 | $0.23 |
| Diluted EPS | $0.54 | $0.19 | $0.38 | $0.23 |
| Weighted Avg Shares Outstanding | $136.76M | $136.73M | $135.62M | $135.19M |
| Weighted Avg Shares Outstanding (Diluted) | $139.77M | $139.71M | $138.06M | $136.98M |
Over the past four quarters, Globus Medical, Inc. demonstrated steady revenue growth, increasing from $629.69M in Q2 2024 to $598.12M in Q1 2025. Operating income reached $97.004M in Q1 2025, maintaining a consistent 16% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $164.13M, reflecting operational efficiency. Net income rose to $75.46M, with EPS at $0.55. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan